Top

Published in:

Open Access 01-04-2019 | Rituximab | Review Article

High-dose etoposide could discriminate the benefit from autologous peripheral blood stem cell transplantation in the patients with refractory diffuse large B cell lymphoma

Authors: Yu Cai, Liping Wan, Juan Yang, Jun Zhu, Jieling Jiang, Su Li, Xianmin Song, Chun Wang

Published in: Annals of Hematology | Issue 4/2019

Abstract

To evaluate the strategy of using high-dose etoposide mobilization followed by autologous peripheral blood stem cell transplantation (APBSCT) in patients with diffuse large B cell lymphoma (DLBCL) refractory to rituximab-based chemotherapy. Forty patients with refractory DLBCL were treated with high-dose etoposide for stem cell mobilization. All patients were in progressive disease (PD) prior to mobilization and underwent high-dose chemotherapy followed by APBSCT. Successful PBSC mobilization was achieved in all patients. Twenty-three patients (57.5%) showed a clinical response to high-dose etoposide. After APBSCT, 17 patients (42.5%) achieved CR. The 2-year progression-free (PFS) and overall survival (OS) rate were higher in patients responding to high-dose etoposide (64.1% and 77.7%) compared to those without response (11.8% and 11.8%; P < 0.001 for both). The response to high-dose etoposide mobilization therapy was an independent prognostic factor for CR achievement, PFS and OS after APBSCT. High-dose etoposide mobilization chemotherapy followed by APBSCT could rescue a proportion of patients with refractory DLBCL who responded to etoposide mobilization regimen.

Chaganti S, Illidge T, Barrington S, Mckay P, Linton K, Cwynarski K, McMillan, British Committee for Standardsin Haematology et al (2016) Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol 174(1):43–56CrossRefPubMed

Sehn LH, Gascoyne RD (2015) Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood 125(1):22–32CrossRefPubMed

Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT et al (2014) Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 32(31):3490–3496CrossRefPubMed

Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H (2016) Diffuse large B-cell lymphoma version 1.2016. J Natl Compr Cancer Netw 14(2):196–231CrossRef

Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY et al (2017) Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation. J Clin Oncol 35:24–31CrossRefPubMed

Hamadani NEM et al (2017) Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: current controversies and advances. Hematol Oncol Stem Cell Ther 10(4):277–228CrossRefPubMed

Vaidya R, Witzig TE (2014) Prognostic factors for diffuse large B-cell lymphoma in the R(X) CHOP era. Ann Oncol 25(11):2124–2133CrossRefPubMedPubMedCentral

Aksentijevich LL, Jones RJ, Ambinder RF, Garrett-Mayer E, Flinn IW et al (2006) Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant 12(9):965–972CrossRefPubMed

Yamamoto M, Watanabe K, Fukuda T, Miura O (2017) Prediction of prognosis for patients with diffuse large B-cell lymphoma refractory to or in first relapse after initial R-CHOP therapy: a single-institution study. Anticancer Res 37(5):2655–2662CrossRefPubMed

10.

Caballero M, Pérez-Simón JA, Iriondo A, Lahuerta JJ, Sierra J, Marín J et al (2003) High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 14(1):140–151CrossRefPubMed

11.

Rodriguez J, Caballero MD, Gutierrez A, Solano C, Arranz R, Lahuerta JJ, Sierra J, Gandarillas M, Perez-Simon JA, Zuazu J, Lopez-Guillermo A, Sureda A, Carreras E, Garcia-Laraña J, Marin J, Garcia JC, Fernandez de Sevilla A, Rifon J, Varela R, Jarque I, Albo C, Leon A, SanMiguel J, Conde E (2004) Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin’s lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. Ann Oncol 15(10):1504–1509CrossRefPubMed

12.

Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28(27):4184–4190CrossRefPubMedPubMedCentral

13.

Kewalramani T, Zelenetz AD, Nimer SD et al (2004) Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103:3684–3688CrossRefPubMed

14.

Vellenga E, van Putten WL, van 't Veer MB, Zijlstra JM, Fibbe WE, van Oers MH et al (2008) Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20 NHL: a prospective randomized HOVON trial. Blood 111(2):537–543CrossRefPubMed

15.

Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E (2006) High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. Leuk Lymphoma 47(8):1545–1552CrossRefPubMed

16.

You B, Salles G, Bachy E, Casasnovas O, Tilly H, Ribrag V, Sebban C, Hénin E, Guitton J, Tod M, Freyer G (2015) Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the Lymphoma Study Association (LYSA). Cancer Chemother Pharmacol 76(5):939–948CrossRefPubMed

17.

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586CrossRefPubMed

18.

Bruserud O, Reikvam H, Kittang AO, Ahmed AB, Tvedt TH, Sjo M et al (2012) High-dose etoposide in allogeneic stem cell transplantation. Cancer Chemother Pharmacol 70(6):765–782CrossRefPubMed

19.

Ozkan HA, Bal C, Gulbas Z (2014) Chemomobilization with high-dose etoposide and G-CSF results in effective and safe stem cell collection in heavily pretreated lymphoma patients: report from a single institution study and review. Eur J Haematol 92(5):390–397CrossRefPubMed

20.

Dunleavy K, Pittaluga S, Maeda LS, Advani R et al (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368(15):1408–1416CrossRefPubMedPubMedCentral

21.

Nagle SJ, Woo K, Schuster SJ, Nasta SD, Stadtmauer E, Mick R, Svoboda J (2013) Outcomes of patients with relapsed/refractory diffuse large B-cell lymphomawith progression of lymphoma after autologous stem cell transplantation inthe rituximab era. Am J Hematol 88(10):890–894CrossRefPubMed

22.

Seshadri T, Stakiw J, Pintilie M, Keating A, Crump M, Kuruvilla J (2008) Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy. Hematology 13(5):261–266CrossRefPubMed

23.

Telio D, Fernandes K, Ma C, Tsang R, Keating A, Crump M, Kuruvilla J (2012) Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors. Leuk Lymphoma. 53(5):836–841CrossRefPubMed

24.

Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO et al (2001) Autologous transplantation for diffuse aggressive non-Hodgkin’s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 19(2):406–413CrossRefPubMed

25.

Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM (2008) Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 26(30):4952–4957CrossRefPubMed

26.

Rizzieri DA, Sand GJ, McGaughey D, Moore JO, DeCastro C, Chao NJ et al (2004) Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma. Cancer 100(11):2408–2414CrossRefPubMed

27.

Güner ŞI, Yanmaz MT, Selvi A, Usul C, Selvi A (2016) The high effect of chemomobilization with high-dose etopside + granulocyte-colony stimulating factor in autologous hematopoietic peripheral blood stem cell transplantation: a single center experience. Hematol Rep 8(1):6319PubMedPubMedCentral

28.

Hyun SY, Cheong JW, Kim SJ, Min YH, Yang DH, Ahn JS et al (2014) High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma previously treated with CHOP-based chemotherapy: a study from the Consortium for Improving Survival of Lymphoma. Biol Blood Marrow Transplant 20(1):73–79CrossRefPubMed

29.

Crocchiolo R, Castagna L, Garciaz S, Fürst S, El Cheikh J et al (2015) Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients. Haematologica 100(10):e423–e427CrossRefPubMedPubMedCentral

30.

Reddy NM, Oluwole O, Greer JP et al (2014) Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma. Exp Hematol 42:39–45CrossRefPubMed

31.

Freytes C’s O, Loberiza FR, Douglas Rizzo J et al (2004) Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 104:3797–3803CrossRefPubMed

32.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531–2544CrossRefPubMedPubMedCentral

33.

Nair RL, Neelapu SS et al (2018) The promise of CAR T-cell therapy in aggressive B-cell lymphoma. Best Pract Res Clin Haematol 31(3):293–298CrossRefPubMedPubMedCentral

Title: High-dose etoposide could discriminate the benefit from autologous peripheral blood stem cell transplantation in the patients with refractory diffuse large B cell lymphoma
Authors: Yu Cai
Liping Wan
Juan Yang
Jun Zhu
Jieling Jiang
Su Li
Xianmin Song
Chun Wang
Publication date: 01-04-2019
Publisher: Springer Berlin Heidelberg
Keywords: Rituximab
Rituximab
Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Stem Cell Transplantation
Stem Cell Transplantion
Stem Cell Transplantation
Cytostatic Therapy
Published in: Annals of Hematology / Issue 4/2019
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-019-03605-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

High-dose etoposide could discriminate the benefit from autologous peripheral blood stem cell transplantation in the patients with refractory diffuse large B cell lymphoma

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2019

A case report of congenital erythropoietic anemia II in China with a novel mutation

Low-dose splenic irradiation is an alternative therapy for symptomatic splenomegaly in patients with myelofibrosis

Vascular density and inflammatory infiltrate in primary oral squamous cell carcinoma and after allogeneic hematopoietic stem cell transplantation

Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia.

An under-recognized cause of copper deficiency mimicking myelodysplastic syndrome

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page